Source Articles
PARP inhibitor
Showing 6 study arms
with grade ≥3 adverse event data (treatment-related and RT-related).
Click a column header to sort.
Note on patient counts: some articles reported only percentages rather
than absolute numbers. Where this occurred, the number of patients — including those with
grade ≥3 adverse events — was derived by applying the reported percentage to the total arm
size, which may produce a non-integer value. These figures have been rounded to the nearest
integer for display.
| 1st Author | Year | Study Type | Title | DOI | clinical trial number | number of patients | median/mean age | median follow-up [months] | tumor type | treatment setting | drug group | drug name | if other, please specify | number of SBRT courses | intracranial / extracranial | treated site | If other treated site, please specify | median/mean total RT dose [Gy] | minimum total RT dose [Gy] | maximum total RT dose [Gy] | median/mean number of fractions | minimum number of fractions | maximum number of fractions | median/mean dose per fraction [Gy] | minimum dose per fraction [Gy] | maximum dose per fraction [Gy] | toxicity type | patients with acute G>=3 toxicity | patients with late G>=3 toxicity | patients with G>=3 toxicity, timing unspecified | G>=3 AEs | patients with G>=3 AEs | details on G>=3 toxicity | details on G>=3 toxicity in RT field |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 2 | 62.0 | 18.0 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | PARP inhibitor | Olaparib | — | Missing | intra-cranial | brain | — | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 0 | — | — |
—
|
—
|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 1 | 62.0 | 18.0 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | PARP inhibitor | Olaparib | — | Missing | extra-cranial | lung | — | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 0 | — | — |
—
|
—
|
| Looman et al. | 2026 | Prospective | Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy | 10.1001/jamanetworkopen.2025.53809 | — | 1 | 62.0 | 18.0 | Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other | oligometastatic, metastatic | PARP inhibitor | Olaparib | — | Missing | extra-cranial | other | Abdomen | — | — | — | Missing | 1 | 10 | — | — | — | RT-related | — | — | 0 | — | — |
—
|
—
|
| Macchia et al. | 2025 | Retrospective | Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective Study. | 10.1016/j.ijrobp.2024.09.010 | — | 74 | 52.0 | 18.0 | other | oligometastatic | PARP inhibitor | Niraparib, Olaparib, Rucaparib | — | 158 | both | brain, LN unspecified, other | abdomen, thorax, pelvis, neck, unspecified 'parenchyma' | 40 | 25 | 55 | 5 | 1 | 10 | 8 | 5 | 16 | RT-related | 2 | 1 | — | acute G3: 2 AEs, late G3: 1 AE | acute G3: 2 pts, late G3: 1 pt |
acute G3: dysphagia, thrombocytopenia, late G3: skin toxicity
|
unknown
|
| Durante et al. | 2024 | Retrospective | Stereotactic radiotherapy for managing ovarian cancer oligoprogression under poly (ADP-ribose) polymerase inhibitors (PARPi) | 10.1136/ijgc-2024-005361 | — | 46 | 58.5 | 25.9 | other | oligometastatic | PARP inhibitor | Niraparib, Olaparib, Rucaparib, Missing | — | 63 | extra-cranial | lung, liver, bone, cervical lymph nodes, thoracic LN, abdominal LN, inguinal LN, pelvic LN | — | 25 | 15 | 50 | 5 | 3 | 10 | 8 | 5 | 10 | RT-related | 0 | 0 | 0 | — | — |
—
|
—
|
| Kroeze et al. | 2021 | Retrospective | Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaSTT' database | 10.1186/s13014-020-01730-0 | — | 1 | 63.0 | 18.7 | Lung cancer | metastatic | PARP inhibitor | Missing | — | 192 | any | brain, lung, liver, adrenal gland, bone, LN unspecified, other | Soft tissue (whole group) | Missing | Missing | Missing | Missing | 1 | 5 | Missing | Missing | Missing | RT-related | 0 | 0 | — | — | — |
—
|
—
|